GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » Beta

RetinalGenix Technologies (RetinalGenix Technologies) Beta : N/A (As of May. 17, 2024)


View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-17), RetinalGenix Technologies's Beta is Not available.


RetinalGenix Technologies Beta Historical Data

The historical data trend for RetinalGenix Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RetinalGenix Technologies Beta Chart

RetinalGenix Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beta
- - - -

RetinalGenix Technologies Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RetinalGenix Technologies's Beta

For the Medical Devices subindustry, RetinalGenix Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RetinalGenix Technologies's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's Beta distribution charts can be found below:

* The bar in red indicates where RetinalGenix Technologies's Beta falls into.



RetinalGenix Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


RetinalGenix Technologies  (OTCPK:RTGN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


RetinalGenix Technologies Beta Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954
RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.